. All times are London time.

Markets data & tools
Aerospace & defence
Basic industries
Consumer industries
Drugs & healthcare
Energy & mining
Financial services
Professional services
Retailing & leisure
Comment & analysis
Your money
Arts & Weekend
Jobs & education
In today's FT
Site services
FT Reports
Creative Business
World reports
Special reports

   Martin Wolf
 Lucy Kellaway
 Philip Stephens
 Amity Shlaes
 Gerard Baker

   Iraq's WMD: Was war justified?
 EU referendum
 UK house prices
 China's economic growth

Partner sites
 Hoover's Online
 Les Echos
 FT Deutschland
 CBS MarketWatch
 Investors Chronicle

Industries / Drugs & healthcare Print article | Email
UK advises against GSK's Seroxat for children
By Josephine Cumbo in London
Published: June 10 2003 12:26 | Last Updated: June 10 2003 12:26

GlaxoSmithKline suffered a blow on Tuesday when UK health regulators told doctors to stop prescribing Seroxat, the group's blockbuster anti-depressant, to under 18s and said the use of the drug by adults was also under review.

Seroxat, known as Paxil in the US, is one of the world's most widely used anti-depressants and had sales last year of 2bn ($3.3bn). Over the past year about 4m prescriptions for the drug were written, with an estimated 8,000 patients being under 18.

The new advice to doctors came after a two-week review into Seroxat and other anti-depressants by the government's Medicine's and Healthcare Products Regulatory Agency.

The review - sparked by complaints of adverse reactions in Seroxat patients - found an increase in the rate of self harm and potentially suicidal behaviour in children and teenagers under 18.

"It has become clear that the benefits of Seroxat in children for the treatment of depressive illnesses do not outweigh the risks," the agency said.

Seroxat is not currently licensed for use in children, but is often prescribed to under 18s at their doctor's discretion.

"It is therefore important that doctors, patients and parents are aware of the new advice," said Professor Gordon Duff, chairman of the Committee on Safety on Medicines.

An expert group investigating SSRIs, the class of anti-depressants known as selective serontonin retake inhibitors, which include Prozac, will now be "examining urgently" the implications of the new findings for Seroxat use in over 18s.

Richard Brook, chairman of the mental health charity MIND, which raised the concerns of Seroxat users, said: "MIND strongly believes that the decision today [Tuesday] requires us to move very quickly forward on the review of Seroxat and other SSRIs, especially given the strength of concern we've heard from people taking these drugs."

Shares in GSK were 3p lower at 12.58 in late morning trade in London.

email this EMAIL THIS print this PRINT THIS most popular MOST POPULAR  
Related stories
Warning for drugs giants on tackling third world risks  Jun 09 2003 05:00
GSK hit by $22m Xerox pay-out  Jun 06 2003 05:00 Requires subscription
'When push comes to shove - we shove'  Jun 05 2003 18:05 Requires subscription
The silver lining of the 'post-bubble' era  Jun 02 2003 05:00 Requires subscription
Time to give top dogs smaller bones  May 28 2003 05:00 Requires subscription
GSK moves swiftly to revamp board  May 26 2003 05:00 Requires subscription
The GSK tsunami ripples will be long felt  May 26 2003 05:00 Requires subscription
Taking the private route  May 26 2003 05:00 Requires subscription
Knives out for 'damaged' directors  May 24 2003 05:00 Requires subscription
Platinum parachute lets Sir Christopher down  May 24 2003 05:00 Requires subscription
Requires subscription = requires subscription to FT.com
Search & quotes

  • Power searchRequires subscription
  • My portfolio

  • Editor's choice
      GlaxoSmithKline faces criticism on Seroxat

    GSK in drive to buy up drugs rights Requires subscription

    Garnier's GSK pay package may be rejected Requires subscription

    GSK proposes boardroom changes to deflect critics Requires subscription

    Calpers to take stance on executive pay at GSK Requires subscription

    Related stories
      Warning for drugs giants on tackling third world risks

    GSK hit by $22m Xerox pay-outRequires subscription

    'When push comes to shove - we shove'Requires subscription

    The silver lining of the 'post-bubble' eraRequires subscription

    Time to give top dogs smaller bonesRequires subscription

    Company data
      GlaxoSmithKline PLC

    Email & tools
       News by email
     Personal office
     Download news ticker
     Currency converter

    Research tools
       Analyst reports
     Business research
     Free annual reports
     Market research
     Growth companies

      Home World | Business | Markets news | Markets data & tools | Industries | Lex | Your money | Comment & analysis | Reports | Arts & Weekend | Sport | Jobs & education | In today's FT | Media inquiries Contact us | Help